Birmingham Health Innovation Campus (BHIC), is set to become a world-leading life sciences campus. Due to open in 2023, it will offer high quality laboratory, office, incubation and innovation facilities for forward-thinking businesses and will be part of an integrated, physically connected critical cluster of patient-centred health excellence.
The campus is being delivered through a long-term collaboration between the University of Birmingham, as landowner, and experienced investor-developers Bruntwood SciTech. It will become the only science park in the region dedicated to health and life sciences, sitting at the heart of a critical cluster of health excellence, led by BHP, creating opportunities for transformative collaborations between businesses, the University and NHS partners.
The campus will provide cutting-edge innovation facilities, building on our nationally recognised strengths in healthcare data, genomics medicine and diagnostics, medical technologies and clinical trials.
Working closely with Bruntwood SciTech, we recently concluded a public consultation into the development which allowed members of the public and interested parties to learn more about our vision and to share their feedback. Although the consultation has now closed, a recording of the public webinar along with details of the plans are available at the consultation website www.bhicconsultation.co.uk.
Our unique concentration of prestigious education, research and clinical institutions makes Birmingham one of the few global cities truly equipped to deliver co-located, integrated health & life sciences expertise. And, with an open and inclusive culture, we will create an environment where businesses will thrive.
BHIC is the only science park in the region dedicated to health and life sciences, sitting at the heart of a critical cluster of health excellence, led by a strategic health partnership – Birmingham Health Partners (BHP) – creating opportunities for transformative collaborations between businesses, the University and NHS partners.
The campus will provide a rare opportunity to expand the BHP offer to businesses at all stages of their developing, allowing them to work in partnership with our outstanding researchers, clinicians and policy makers, as well as our large and diverse patient population. As a result, scientific and clinical insights and industry innovation will be rapidly translated into patient benefit and economic growth.
As one of only six national Life Sciences Opportunity Zones, BHIC is attracting significant new inward investment to the region – including £10.8m from the Government’s Getting Building Fund (GBF) which aims to drive economic recovery post-coronavirus, and will catalyse a new high-growth health and life sciences cluster for the city and region.
BHIC is set to drive:
A 10-year masterplan will be developed for the Campus, which will provide up to 700,000 sq ft of state-of-the-art lab, office and incubation space acting as a catalyst for the growth of the Midlands’ life sciences sector. It is set to create over 10,000 new jobs and contribute £400m GVA to the regional economy by 2030.
Download our BHIC Project Update pdf to learn more about our plans, including the Resilience in Supply Chains for Med Tech Manufacturing (ReSCue) project, which will support manufacturing businesses and supply chains to diversify, scale-up and increase their resilience.
This signature facility will be the focal point of the development, providing up to 6,000sqm of innovation, co-creation and incubation space within our Phase 1 building.
The Precision Health Technologies Accelerator (PHTA) will be dedicated to the rapid development and translation of innovative therapies and technologies from concept to clinical evaluation. By creating new opportunities for businesses and entrepreneurs to innovate and grow, and for clinical-academics in the region to commercialise their ideas, it will accelerate our ambition to be a research and innovation leader in health and life sciences.
The PHTA builds on BHP’s nationally-recognised strengths and will support businesses through access to expertise in:
- the development and delivery of complex clinical trials
- complex diagnostics, multi-omics analysis and heath data
- device evaluation and testing
- regulatory science and innovation
The PHTA will provide the early incubation, grow-on space and innovation services for businesses working across biopharma, advanced therapies, diagnostics, digital health and healthcare technologies to accelerate the development and delivery of new drugs, diagnostics and devices into clinic. Its incubation services for early-stage businesses are set to include wet labs, dry labs and office spaces, and prototype development facilities.
Why is the campus being developed?
Increasingly, the use of data and new technologies is enabling patient stratification and improved targeting of healthcare interventions, in turn allowing innovations from across sectors to be applied to the patient.
With both new entrants and established health and life sciences firms seeking novel approaches, the need to de-risk innovations – in diagnostics, software, devices or new therapies – through testing and evaluation in a relevant real-world environment is critical if we are to successfully commercialise and adopt new technologies.
Providing a bespoke physical home for collaborative research and data-enabled healthcare innovation, BHIC will also create the open and inclusive culture, infrastructure and environment needed to deliver key elements of the Government’s Life Sciences Industrial Strategy. This includes the mission to ‘transform the prevention, early diagnosis and treatment of diseases like cancer, diabetes, heart disease and dementia by 2030’.
The campus is set to attract innovative businesses to the region, and will support them to create meaningful employment opportunities and sustainable economic growth to benefit both patients and the wider community. It will also create the grow-on space for the businesses currently incubating in The BioHub Birmingham which is fully occupied.
Will there be space at Birmingham Health Innovation Campus for companies to locate?
Yes – our first Phase building, including the Precision Health Technologies Accelerator (see above), is set to provide up to 12,000sqm (133,000sqft) of innovation, co-creation and incubation space.
Future phases have the potential for around 65,000sqm (650,000sqft) of lettable commercial space for innovative health and life sciences businesses seeking to co-locate and work closely with BHP. This will comprise high-quality lab and office space for new start-ups, alongside grow-on space for businesses either currently incubating at our existing BioHub, Institute of Translational Medicine, or elsewhere. The potential for flexible design will also enable businesses to configure their own space as they scale up.
There is also the option of developing pre-lets for established businesses seeking to relocate or co-locate teams at the heart of the BHP ecosystem.
And if you are concerned about there not being enough space for your business growth in the future, we can link you to a number of nearby developments in Birmingham that can offer additional space, ensuring that your business remains connected to the ecosystem once here.
What other facilities will there be for businesses?
As well as lab and office spaces, the campus will provide communal and training spaces to foster a vibrant and collaborative community. This is expected to include café and breakout areas, a co-creation ‘makerspace’, plus dedicated spaces for events, meetings and specialist training.
We are part of an entrepreneurial culture, with an existing infrastructure of technical leadership and entrepreneurial skills that will support our resident businesses to grow. We will also provide a full range of business development support, including access to clinicians, IP protection and regulatory support.
What are the timelines for the development?
We anticipate that phased construction will start on site in early 2021. Other opportunities are available in the meantime; we are currently developing partnerships and activities in areas such as the design and delivery of clinical trials and genomics sciences. Please contact us using the details below if you would like to find out more about these activities and partnering with us.
Can I invest in BHIC?
There are still opportunities for partners wishing to invest in the development of the park and we are happy to discuss these with interested parties. Please contact us for more information.
How will patients be involved?
Everything Birmingham Health Partners stands for is centred on the patient: their accurate diagnosis, personalised care, and long-term wellbeing. The patient’s outcome is always at the heart of the work we undertake – and many projects have been directly inspired by our patients’ experiences.
BHIC will extend this ground-breaking development of new products and services, giving patients earlier access to medical innovations such as diagnostics, devices and drugs.
While patients will not be treated on the park, they are always a valuable part of our research processes. You can find out more about our approach on our Patient and Public Involvement page.
We will also bring our knowledge and experience in patient-reported outcomes (PROs) to demonstrate the value of diagnostic, pharmaceutical and other medical technology innovations. Optimising the use of PROs will enable businesses working with us to improve service delivery, enhance patient care and outcomes, and ensure that the patient perspective is at the heart of health research.